<DOC>
	<DOC>NCT00606060</DOC>
	<brief_summary>Phase III study, to evaluate the efficacy and safety of continuous infusion of rFVIII-FS in the treatment of patients with hemophilia A undergoing major elective surgery by achieving the required therapeutic concentrations.</brief_summary>
	<brief_title>BAY14-2222 Continuous Infusion in Surgeries</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A (FVIII:C &lt;/=1%) No history of FVIII inhibitor formation and no current evidence of inhibitor antibody (Bethesda Assay &lt; 0.6 BU) Elective major surgery requiring at least 6 days of rFVIIIFS therapy Subjects should have been previously treated with FVIII concentrates for at least 150 exposure days. Previous treatment could have been with any type of rFVIII or with plasmaderived FVIII concentrate or cryoprecipitate Abnormal renal function (serum creatinine &gt;1.3 mg/dL) Any treatments, which may change the clearance of FVIII (dialysis, plasma exchange) Anemia (hemoglobin &lt;11 g/dL) Known AIDS (HIV seropositive patients may be enrolled) Active liver disease (transaminases &gt; 5 times the upper limit of normal) History of severe reaction to FVIII concentrates Interferon treatment within the last 3 months Thrombocytopenia (&lt; 100,000 platelets/mm3) or other known hematological/bleeding problems other than hemophilia A Intake of other investigational drugs within 1 month prior to study entry Need for premedication for FVIII infusions (e.g. antihistamines) Diastolic blood pressure &gt;100 mm/Hg, which could not be controlled with antihypertensive medications</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Hemophilia,</keyword>
	<keyword>Continuous Infusion</keyword>
</DOC>